Press Release FeedGet the RSS feed
Menu

Browse press releases

The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.

5,225 resultsPage 68 of 436, newest first
  1. AI兩位前莫德納腫瘤疫苗資深科學家加盟 雲頂新耀mRNA全球臨床開發提速香港, 2026年10月9日 - 雲頂新耀（1952.HK）宣佈任命Lakshmi Srinivasan博士擔任高級副總裁、轉化醫學負責人，Brandon Coder博士擔任轉化科學與早期研究副總裁。兩位新任高管均擁有深厚的行業經驗和專業背景，此前曾在莫德納等全球領先的生物制藥企業負責腫瘤疫苗研發，具備從早期發現到臨床轉化及臨床開發的完整實戰經驗。 此次重磅引才，是雲頂新耀加速推進mRNA全球戰略的關鍵舉措，將進一步強化雲頂新耀mRNA技術平台的全球研發能力與國際合作佈局。兩位科學家將在雲頂新耀管理層的領導下，重點推動雲頂新耀mRNA技術平台在美國的臨床開發及相關業務佈局，並與中國研發團隊密切協作，進一步賦能mRNA技術平台的進化。 值得關注的是，兩位科學家此前所任職的莫德納，是全球mRNA腫瘤治療領域最具代表性的企業之一。2026年8月，莫德納與默沙東宣佈，mRNA-4157/V940聯合Keytruda在III期INTerpath-001研究中達到無複發生存期主要終點及無遠處轉移生存期關鍵次要終點，成為首個在III期臨床研究中取得陽性結果的mRNA腫瘤療法及個體化新抗原療法。此前，IIb期KEYNOTE-942研究五年隨訪結果也顯示，該聯合方案相較於Keytruda單藥可降低患者複發或死亡風險及遠處轉移或死亡風險。目前，相關研發已拓展至多個癌種。兩位科學家此前在莫德納參與相關腫瘤疫苗項目，積累了從早期研究到臨床開發的實踐經驗，為雲頂新耀進一步推進自主mRNA平台的全球臨床開發提供了重要專業支撐。 雲頂新耀董事會主席吳以芳表示：「我們非常高興Srinivasan博士和Coder博士加入雲頂新耀。兩位資深科學家在腫瘤疫苗研發、轉化醫學及臨床開發領域擁有深厚經驗，將進一步強化公司的全球mRNA研發能力，助力推進自主mRNA技術平台及相關產品管線的全球臨床開發。此次任命體現了雲頂新耀持續匯聚全球頂尖人才、推進全球mRNA戰略的承諾。」 據了解，Srinivasan博士擁有20年腫瘤免疫領域研發經驗，作為資深免疫學家，她長期致力於推動創新腫瘤免疫療法從早期發現研究走向臨床開發，在腫瘤疫苗、mRNA-LNP（脂質納米顆粒）技術、T細胞療法及轉化醫學開發等領域擁有豐富經驗，研發經驗覆蓋從臨床前研究到臨床概念驗證的多個階段。加入雲頂新耀前，Srinivasan博士於2023年至2025年就職於莫德納（Moderna Therapeutics），曾任執行總監、腫瘤轉化醫學負責人；此前她曾任Repertoire Immune Medicines副總裁、臨床前科學與轉化醫學負責人，Neon Therapeutics（後並入BioNTech）轉化科學高級總監及賽諾菲（Sanofi）腫瘤藥物發現負責人。Srinivasan博士長期從事個性化新抗原疫苗臨床轉化研究，並在該領域發表多篇高影響力學術論文。她作為通訊作者參與了NEO-PV-01的Ib期臨床研究，相關研究成果分別發表於《Cell》（2020年）和《Cancer Cell》（2022年）。此外，她也作為共同作者參與了莫德納 intismeran autogene（mRNA-4157/V940）的多篇代表性論文，包括發表於《Cancer Discovery》（2024年）的I期KEYNOTE-603研究中mRNA-4157/V940單藥及聯合帕博利珠單抗治療所誘導的T細胞應答；以及發表於《JCO Oncology Advances》（2026年）的mRNA-4157/V940聯合帕博利珠單抗治療切除後黑色素瘤的隨機IIb期 KEYNOTE-942研究3年隨訪結果。 Coder博士擁有超過11年的生物醫藥行業研發經驗，長期致力於推動T細胞免疫療法從早期發現研究走向IND申報及早期臨床概念驗證。他在腫瘤疫苗、mRNA/LNP平台技術及in vivo CAR療法領域擁有豐富經驗。加入雲頂新耀前，他於2019年至2025年任職莫德納，曾任腫瘤疫苗研究及早期臨床轉化負責人、副科學總監，並擔任mRNA-4157/V940的研究、早期轉化及全球藥理學負責人——該產品於2026年8月公佈III期INTerpath-001研究陽性結果，成為全球首個在III期臨床中取得成功的個性化新抗原療法及mRNA腫瘤療法。他還是莫德納共享抗原腫瘤疫苗mRNA-4359的共同發明人及研究負責人，並是共享抗原疫苗策略及設計框架的共同發明人，相關策略應用於莫德納共享抗原腫瘤疫苗產品組合。此外，他作為共同發明人、研究負責人或核心貢獻者參與了9項IND申報，也是《Cancer Discovery》（2024年）KEYNOTE-603研究論文的共同作者。加入莫德納前，他曾任Advaxis Immunotherapies腫瘤免疫研發副總監及腫瘤疫苗研究負責人。 基於自主知識產權的AI+mRNA平台，雲頂新耀正多路徑推進mRNA腫瘤治療性疫苗和自體生成CAR-T平台，治療腫瘤及自身免疫疾病。目前，個性化腫瘤治療性疫苗EVM16完成首次人體臨床數據讀出，顯示出良好的安全性、耐受性、顯著的免疫原性及積極的初步療效信號，部分數據已於2026年美國癌症研究協會（AACR）年會上公佈。EVM16計劃於2026年第四季度啟動IIT（研究者發起的臨床試驗）Ib期臨床研究，並在Ia研究基礎上，開展新的適應症擴展隊列，進行有效性探索，並計劃於2027 H1遞交美國食品藥品監督管理局（FDA）新藥臨床試驗（IND）申請；通用現貨型腫瘤相關抗原（TAA）疫苗EVM14，繼2025年相繼獲得美國FDA及中國國家藥品監督管理局「雙重IND」批准後，公司將於2027年第一季度完成臨床I期單藥劑量遞增；自體生成CAR-T療法EVM18已啟動針對自身免疫疾病的IIT研究，同時公司正穩步推進其全球IND申報工作；免疫調節腫瘤疫苗EVM15於2025年取得臨床前概念驗證，確定臨床候選分子，公司計劃於2026年推進EVM15的新藥臨床試驗申請准備工作。 兩位腫瘤疫苗資深科學家的加盟，是雲頂新耀加速mRNA全球戰略的關鍵一步，也體現了公司全球研發資源與人才實力的快速提升。隨著國際化團隊持續壯大、全球資源加速匯聚，雲頂新耀將進一步鞏固自主AI+mRNA平台的技術優勢，推動mRNA腫瘤疫苗及自體生成CAR-T管線在全球範圍內梯次落地，持續深化全球化佈局，為全球患者帶來更多創新治療選擇。
  2. AI两位前莫德纳肿瘤疫苗资深科学家加盟 云顶新耀mRNA全球临床开发提速香港, 2026年10月9日 - (亚太商讯) - 云顶新耀（1952.HK）宣布任命Lakshmi Srinivasan博士担任高级副总裁、转化医学负责人，Brandon Coder博士担任转化科学与早期研究副总裁。两位新任高管均拥有深厚的行业经验和专业背景，此前曾在莫德纳等全球领先的生物制药企业负责肿瘤疫苗研发，具备从早期发现到临床转化及临床开发的完整实战经验。 此次重磅引才，是云顶新耀加速推进mRNA全球战略的关键举措，将进一步强化云顶新耀mRNA技术平台的全球研发能力与国际合作布局。两位科学家将在云顶新耀管理层的领导下，重点推动云顶新耀mRNA技术平台在美国的临床开发及相关业务布局，并与中国研发团队密切协作，进一步赋能mRNA技术平台的进化。 值得关注的是，两位科学家此前所任职的莫德纳，是全球mRNA肿瘤治疗领域最具代表性的企业之一。2026年8月，莫德纳与默沙东宣布，mRNA-4157/V940联合Keytruda在III期INTerpath-001研究中达到无复发生存期主要终点及无远处转移生存期关键次要终点，成为首个在III期临床研究中取得阳性结果的mRNA肿瘤疗法及个体化新抗原疗法。此前，IIb期KEYNOTE-942研究五年随访结果也显示，该联合方案相较于Keytruda单药可降低患者复发或死亡风险及远处转移或死亡风险。目前，相关研发已拓展至多个癌种。两位科学家此前在莫德纳参与相关肿瘤疫苗项目，积累了从早期研究到临床开发的实践经验，为云顶新耀进一步推进自主mRNA平台的全球临床开发提供了重要专业支撑。 云顶新耀董事会主席吴以芳表示：“我们非常高兴Srinivasan博士和Coder博士加入云顶新耀。两位资深科学家在肿瘤疫苗研发、转化医学及临床开发领域拥有深厚经验，将进一步强化公司的全球mRNA研发能力，助力推进自主mRNA技术平台及相关产品管线的全球临床开发。此次任命体现了云顶新耀持续汇聚全球顶尖人才、推进全球mRNA战略的承诺。” 据了解，Srinivasan博士拥有20年肿瘤免疫领域研发经验，作为资深免疫学家，她长期致力于推动创新肿瘤免疫疗法从早期发现研究走向临床开发，在肿瘤疫苗、mRNA-LNP（脂质纳米颗粒）技术、T细胞疗法及转化医学开发等领域拥有丰富经验，研发经验覆盖从临床前研究到临床概念验证的多个阶段。加入云顶新耀前，Srinivasan博士于2023年至2025年就职于莫德纳（Moderna Therapeutics），曾任执行总监、肿瘤转化医学负责人；此前她曾任Repertoire Immune Medicines副总裁、临床前科学与转化医学负责人，Neon Therapeutics（后并入BioNTech）转化科学高级总监及赛诺菲（Sanofi）肿瘤药物发现负责人。Srinivasan博士长期从事个性化新抗原疫苗临床转化研究，并在该领域发表多篇高影响力学术论文。她作为通讯作者参与了NEO-PV-01的Ib期临床研究，相关研究成果分别发表于《Cell》（2020年）和《Cancer Cell》（2022年）。此外，她也作为共同作者参与了莫德纳 intismeran autogene（mRNA-4157/V940）的多篇代表性论文，包括发表于《Cancer Discovery》（2024年）的I期KEYNOTE-603研究中mRNA-4157/V940单药及联合帕博利珠单抗治疗所诱导的T细胞应答；以及发表于《JCO Oncology Advances》（2026年）的mRNA-4157/V940联合帕博利珠单抗治疗切除后黑色素瘤的随机IIb期 KEYNOTE-942研究3年随访结果。 Coder博士拥有超过11年的生物医药行业研发经验，长期致力于推动T细胞免疫疗法从早期发现研究走向IND申报及早期临床概念验证。他在肿瘤疫苗、mRNA/LNP平台技术及in vivo CAR疗法领域拥有丰富经验。加入云顶新耀前，他于2019年至2025年任职莫德纳，曾任肿瘤疫苗研究及早期临床转化负责人、副科学总监，并担任mRNA-4157/V940的研究、早期转化及全球药理学负责人——该产品于2026年8月公布III期INTerpath-001研究阳性结果，成为全球首个在III期临床中取得成功的个性化新抗原疗法及mRNA肿瘤疗法。他还是莫德纳共享抗原肿瘤疫苗mRNA-4359的共同发明人及研究负责人，并是共享抗原疫苗策略及设计框架的共同发明人，相关策略应用于莫德纳共享抗原肿瘤疫苗产品组合。此外，他作为共同发明人、研究负责人或核心贡献者参与了9项IND申报，也是《Cancer Discovery》（2024年）KEYNOTE-603研究论文的共同作者。加入莫德纳前，他曾任Advaxis Immunotherapies肿瘤免疫研发副总监及肿瘤疫苗研究负责人。 基于自主知识产权的AI+mRNA平台，云顶新耀正多路径推进mRNA肿瘤治疗性疫苗和自体生成CAR-T平台，治疗肿瘤及自身免疫疾病。目前，个性化肿瘤治疗性疫苗EVM16完成首次人体临床数据读出，显示出良好的安全性、耐受性、显著的免疫原性及积极的初步疗效信号，部分数据已于2026年美国癌症研究协会（AACR）年会上公布。EVM16计划于2026年第四季度启动IIT（研究者发起的临床试验）Ib期临床研究，并在Ia研究基础上，开展新的适应症扩展队列，进行有效性探索，并计划于2027 H1递交美国食品药品监督管理局（FDA）新药临床试验（IND）申请；通用现货型肿瘤相关抗原（TAA）疫苗EVM14，继2025年相继获得美国FDA及中国国家药品监督管理局“双重IND”批准后，公司将于2027年第一季度完成临床I期单药剂量递增；自体生成CAR-T疗法EVM18已启动针对自身免疫疾病的IIT研究，同时公司正稳步推进其全球IND申报工作；免疫调节肿瘤疫苗EVM15于2025年取得临床前概念验证，确定临床候选分子，公司计划于2026年推进EVM15的新药临床试验申请准备工作。 两位肿瘤疫苗资深科学家的加盟，是云顶新耀加速mRNA全球战略的关键一步，也体现了公司全球研发资源与人才实力的快速提升。随着国际化团队持续壮大、全球资源加速汇聚，云顶新耀将进一步巩固自主AI+mRNA平台的技术优势，推动mRNA肿瘤疫苗及自体生成CAR-T管线在全球范围内梯次落地，持续深化全球化布局，为全球患者带来更多创新治疗选择。 Copyright 2026 亚太商讯. All rights reserved. www.acnnewswire.com
  3. AITwo Former Moderna Cancer Vaccine Scientists Join Everest Medicines, Accelerating Global Development of Its mRNA PlatformHong Kong, Oct 9, 2026 - Everest Medicines (1952.HK) announced the appointments of Lakshmi Srinivasan, PhD, as Senior Vice President, Head of Translational Medicine, and Brandon Coder, PhD, as Vice President, Translational Sciences & Discovery. Both executives are seasoned scientists in mRNA cancer vaccines, with deep experience spanning early discovery through clinical development and leadership roles in oncology vaccine research at Moderna and other leading biopharmaceutical companies. The appointments further strengthen the Company’s global R&D capabilities in mRNA therapeutics, and support the continued advancement of its proprietary mRNA platform and pipeline. At Everest, they will drive clinical development of the Company’s mRNA programs and expand Everest’s presence in the United States, in line with the Company’s global mRNA R&D strategy, while working closely with the China R&D team. The two scientists previously held leadership roles at Moderna, where they contributed to its mRNA cancer vaccine programs, including mRNA-4157/V940. Their experience spanning early-stage research through clinical development will support the advancement of Everest's proprietary mRNA platform and global clinical development programs. In August 2026, Moderna and Merck announced that mRNA-4157/V940 in combination with Keytruda met the primary endpoint of recurrence-free survival (RFS) and the key secondary endpoint of distant metastasis-free survival (DMFS) in the Phase 3 INTerpath-001 study. The results represent the first positive Phase 3 readout for an individualized neoantigen therapy (INT) and for an mRNA-based cancer therapy. “We are very pleased to welcome Dr. Srinivasan and Dr. Coder to Everest Medicines as we continue to strengthen our global mRNA R&D capabilities,” said Mr. Yifang Wu, Chairman of the Board of Everest Medicines. “Their deep experience in cancer vaccine research, translational medicine, and clinical development will be highly valuable as we advance our proprietary mRNA platform and broader pipeline. Their appointments reflect our continued commitment to investing in world-class talent and advancing our global mRNA strategy.” Dr. Srinivasan is a seasoned immunologist with 20 years of experience advancing innovative immuno-oncology therapeutics from discovery through clinical development. Her expertise spans cancer vaccines, mRNA-LNP technologies, T-cell therapies, and translational development from preclinical research through clinical proof of concept. Prior to joining Everest Medicines, Dr. Srinivasan served as Executive Director and Head of Oncology Translational Medicine at Moderna Therapeutics from 2023 to 2025. She previously held leadership roles at Repertoire Immune Medicines, Neon Therapeutics, which was later acquired by BioNTech, and Sanofi Oncology. Dr. Srinivasan has played a key role in the clinical translation of personalized neoantigen vaccines and has authored multiple high-profile publications in the field. She served as corresponding author on Phase 1b studies of NEO-PV-01 published in Cell (2020) and Cancer Cell (2022), and co-authored publications on Moderna’s intismeran autogene (mRNA-4157/V940), including the Phase 1 KEYNOTE-603 study published in Cancer Discovery (2024) and the three-year follow-up of the randomized Phase 2b KEYNOTE-942 study published in JCO Oncology Advances (2026). Dr. Coder brings more than 11 years of industry experience advancing T cell immunotherapies from discovery through investigational new drug (IND) submissions and early clinical proof of concept, with expertise in cancer vaccines, mRNA/LNP platform technology, and in vivo CAR therapies. Prior to joining Everest Medicines, Dr. Coder held scientific roles at Moderna from 2019 to 2025, most recently as Associate Scientific Director of Cancer Vaccine Research. He served as research and global pharmacology lead for intismeran autogene (mRNA-4157/V940), which reported positive results from the Phase 3 INTerpath-001 study in August 2026, becoming the first personalized neoantigen therapy and mRNA cancer therapy to achieve success in a Phase 3 clinical study. Dr. Coder also co-invented and led development of the shared-antigen discovery and vaccine design framework for mRNA-4359 and mRNA-4106. He contributed to nine IND submissions as a co-inventor, research lead, or core contributor, and co-authored the Phase 1 KEYNOTE-603 study of mRNA-4157/V940 published in Cancer Discovery (2024). Prior to joining Moderna, Dr. Coder served as Associate Director of Immuno-Oncology Research at Advaxis Immunotherapies, where he developed personalized and off-the-shelf cancer vaccines. Leveraging its proprietary AI+mRNA platform, Everest Medicines is advancing multiple mRNA oncology therapeutic vaccine and in vivo CAR-T programs for oncology and autoimmune diseases. EVM16, a personalized mRNA therapeutic cancer vaccine, has completed its first-in-human clinical data readout, demonstrating a favorable safety and tolerability profile, robust immunogenicity and promising preliminary efficacy. Selected data were presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting. Following the Phase 1a study, EVM16 plans to initiate an investigator-initiated trial (IIT) Phase 1b study in Q4 2026 and launch new indication expansion cohorts for efficacy exploration. The company plans to submit an IND application to the U.S. Food and Drug Administration (FDA) in the first half of 2027. EVM14, an off-the-shelf tumor-associated antigen (TAA) mRNA cancer vaccine, received IND clearance from the U.S. FDA and IND approval from China’s National Medical Products Administration (NMPA) in 2025. The Phase 1 monotherapy dose-escalation study is expected to be completed in Q1 2027.EVM18, an in vivo CAR-T therapy, has initiated an IIT study in autoimmune diseases, with global IND filing underway. EVM15, an off-the-shelf immunomodulatory (IM) cancer vaccine, achieved clinical proof of concept in preclinical studies in 2025, with a clinical candidate subsequently selected. The Company plans to advance preparations for the Investigational New Drug (IND) application for EVM15 in 2026.
  4. AIAirwheel Advances Smart Travel Through Award-Winning Rideable Ai Wheel 20inch Carry on boarding hand Luxury Cabin SuitcaseBRUSSELS, BELGIUM, Oct 9, 2026 - Most recently, the Airwheel SE3SX Smart Rideable Cabin Suitcase was honored with a 2026 European Product Design Award (EPDA) Winner title, marking yet another milestone in the brand's relentless pursuit of innovation. Airwheel, a pioneering smart mobility brand, has cemented its position as a global design leader with its intelligent rideable luggage series accumulating over 100 prestigious international awards across the United States, Europe, Japan, Italy, Germany, France, and London. The EPDA, alongside the MUSE Design Awards and IDEA Awards—all established by the International Awards Associate (IAA)—represent the pinnacle of global industrial design recognition. An international jury evaluates entries across innovation, aesthetic expression, practical implementation, human-machine interaction, and user experience. Airwheel's repeated success across these platforms underscores its design philosophy: "Let design return to real travel." Award-Winning Products Under the Spotlight Airwheel SE3S Smart Electric Suitcase Award Portfolio: 2023 MUSE Design Award, IDA Award, Italy IIDA Award; 2024 French Design Award, London Design Award (Best of Year), American Good Design Award (Silver), Paris DNA Design Award, NY Product Design Award (Silver); 2025 German National Design Award (Winner), Italy A' Design Award (Silver) MUSE Jury Commentary: "The Airwheel SE3S revolutionizes the traditional suitcase by integrating electric rideability with smart storage. Its patented high-strength frame and modular detachable lithium battery enable seated mobility while meeting stringent aviation regulations—delivering an effortless, elegant travel experience for frequent flyers." As the flagship pioneer of Airwheel's rideable luggage line, the SE3S features a 20-inch carry-on form factor combining rideable transportation, smart storage, and on-the-go charging. Its high-strength hard shell and patented reinforced frame support rider weight, while dual-handlebar controls ensure intuitive operation. The modular plug-and-play lithium battery requires no tools for removal and complies with civil aviation standards. Airwheel SE3SX Smart Rideable Cabin Suitcase Award Portfolio: 2026 European Product Design Award (Winner), WGA Creative Global Design Award (Silver), iLuxury International Luxury Award, Titan Innovation Award (Platinum) EPDA Jury Commentary: "The Airwheel SE3SX redefines the value boundary of carry-on luggage as a 'smart travel terminal,' seamlessly integrating high-performance electric drive, intelligent interaction, and aviation-grade lightweight design. Its innovative electric telescopic front-wheel structure enhances riding stability, while Apple Find My and a dedicated smart app deliver natural human-machine interaction. The 73.26Wh detachable battery and TSA lock ensure global compliance—a design benchmark for premium international business travel." The SE3SX packs a 230W high-performance brushless motor delivering speeds up to 9.9km/h, a 95kg load capacity, and 6° hill-climbing capability. Its innovative electric telescopic front-wheel structure extends the wheelbase by 180mm at the touch of a button. The body combines lightweight ABS+PC materials with an aviation-grade aluminum alloy frame, weighing approximately 6.6kg (excluding power bank), with dimensions of 530×360×236mm and a 20L capacity. Features include Apple Find My global tracking, a dedicated smart app, 5V USB charging, a detachable 73.26Wh lithium battery, and a TSA customs lock—approved for both air and high-speed rail travel. Airwheel SE3SXD Ai Luxury Suitcase The SE3SXD elevates the travel experience with an integrated smart interaction system and linked smart handle, enabling one-touch switching between suitcase form and riding mode. Its dual-drive automatic telescopic mechanism extends and retracts the structure with a single touch—transforming luggage into an intelligent travel companion. Airwheel SE3MiniT Electric Hand Suitcase Award Portfolio: 2024 European Design Award, London Design Award (Platinum), NY Product Design Award (Gold), American Good Design Award (Bronze), Paris DNA Award (Honorable Mention), French Design Award (Honorable Mention); 2025 Italy A' Design Award (Silver), World Design Award European Design Award Jury Commentary: "The Airwheel SE3MiniT addresses urban short-distance travel with ultimate lightweight design, distilling complex rideable luggage functions into a pure 'travel light' experience. Its compact form and convenient rideability make city commutes and weekend getaways effortless—showcasing nuanced thinking for segmented smart mobility scenarios." Designed for urban commuting and weekend excursions, the SE3MiniT retains Airwheel's signature rideable functionality in a compact, lightweight body—ideal for high-frequency, short-distance metropolitan travelers. Airwheel SE3SL / SE3SL+ Ai Wheel Airport Boarding Suitcase Award Portfolio: SE3SL—2025 Berlin Design Award (Gold), Shanghai Design Award, US IDEA Award, IAI Design Award, New Quality Award, Japan IDPA Design Award (Silver), 2026 Asian Design Award; SE3SL+—2025 US AIIDA Design Award, Boiling Quality Award (Gold) IDEA Jury Commentary: "The Airwheel SE3SL organically combines smart mobility concepts with mainstream business luggage forms. At just 6.6kg, its ultra-lightweight design integrates rideability, app connectivity, USB charging, and location tracking—achieving an outstanding balance between innovation, user experience, and commercial value. A mature offering for high-frequency business travel." Targeting premium business travelers, the SE3SL/SE3SL+ series integrates rideable transportation, smart app connectivity, USB charging, and Apple Find My tracking—blending aesthetics with practicality for both short-haul and international business scenarios. Airwheel SQ3S Smart Kids Suitcase Award Portfolio: 2025 French Design Award (Gold), MUSE Design Award (Silver), American Good Design Award (Bronze), NY Product Design Award (Gold) French Design Award Jury Commentary: "The Airwheel SQ3S enters the family travel scene with a safety-first design language, achieving a balance of 'storable, rideable, and reassuring' in a children's smart suitcase. Its safety speed-limit design fully considers children's riding safety, making family travel both fun and secure—embodying design's gentle care for real family needs." The SQ3S is Airwheel's dedicated smart suitcase for family travel, combining ample storage with child-friendly rideable fun, featuring a safety speed-limit design for secure, enjoyable family experiences. Meet Airwheel at the 140th Canton Fair Following its continued recognition in international design competitions, Airwheel invites distributors, importers, retailers, business partners, and visitors from around the world to meet its team at the 140th China Import and Export Fair (Canton Fair) in Guangzhou, China. Airwheel will participate across all three phases of the exhibition, presenting its intelligent rideable luggage and smart mobility solutions to international buyers and industry professionals. Visitors will have the opportunity to explore Airwheel’s product portfolio, experience selected products firsthand, learn more about its latest developments in smart travel technology, and discuss potential distribution partnerships and business opportunities. From smart rideable cabin suitcases to its latest intelligent luggage concepts, Airwheel looks forward to connecting with global partners and exploring opportunities to bring innovative mobility solutions to more markets. Global buyers and potential distribution partners are warmly invited to visit Airwheel’s booths and meet the team in person. Exhibition: 140th China Import and Export Fair (Canton Fair) Venue: China Import and Export Fair Complex, Guangzhou, China Phase 2: October 23–27, 2026 | Booth 20.2F19–20 Phase 3: October 31–November 4, 2026 | Booth 20.2J37–38,20.2K11-12, 18.1K04 For international buyers seeking to expand their smart luggage portfolio, explore retail opportunities, or discuss regional distribution, the Canton Fair provides an opportunity to connect directly with Airwheel and learn more about its products and international partnership opportunities. Brand-Level Honors and Future Outlook As a pioneer of the smart rideable luggage category, Airwheel has built a clear and robust competitive moat through core technologies. To date, the company has secured over 600 patents globally, covering motion control algorithms, electric drive systems, intelligent perception, and structural design—including multiple international invention patents. Airwheel's trademarks are registered in over 168 countries and regions, providing a solid foundation for compliant operations, scalable promotion, and long-term brand building across diverse markets. Behind these honors lies over a decade of deep cultivation in the smart mobility sector. From its first German iF Design Award to now holding over 100 international certifications across the US, Europe, Japan, Italy, France, and the UK, Airwheel continues to showcase the power of persistent innovation. Looking ahead, the brand will continue integrating cutting-edge intelligent perception and human-machine interaction technologies—embedding technology into every journey and delivering smart mobility innovations to global markets. About Airwheel Airwheel is a leading smart mobility brand specializing in intelligent rideable luggage and personal mobility solutions. Guided by its design philosophy “Let design return to real travel”, Airwheel combines electric drive, smart interaction and aviation-grade materials to redefine travel experiences. Boasting over 600 global patents and more than 100 international awards, Airwheel, as one of the world’s leading smart mobility device manufacturers, strives to unleash the joy of technology and uphold its corporate culture: “Free Intelligent Life”. Media Contact Company: Airwheel Contact: Media Team Website: https://www.airwheel.net
  5. AIAirwheel Advances Smart Travel Through Award-Winning Rideable Ai Wheel 20inch Carry on boarding hand Luxury Cabin SuitcaseMost recently, the Airwheel SE3SX Smart Rideable Cabin Suitcase was honored with a 2026 European Product Design Award (EPDA) Winner title, marking yet another milestone in the brand's relentless pursuit of innovation. Airwheel, a pioneering smart mobility brand, has cemented its position as a global design leader with its intelligent rideable luggage series accumulating over 100 prestigious international awards across the United States, Europe, Japan, Italy, Germany, France, and London.
  6. AISAP推動「自主營運企業」落地應用Companies: SAP香港, 2026年10月9日 - SAP在近日舉行的 SAP Connect 大會展示「自主營運企業」（Autonomous Enterprise）的實際應用，演示 Joule Work 與智能助手 Joule Assistants 如何為各業務範疇的客戶創造價值。 SAP 全球行政總裁柯睿安（Christian Klein） 表示：「這是企業級業務人工智能（Business AI）的突破性時刻，自主營運企業的應用正在加速落地。透過基於 SAP Business AI 平台構建的 Joule 及 SAP Autonomous Suite，我們正協助諾華（Novartis）、Morgan Foods、雀巢（Nestlé）及普華永道（PwC）等機構，在不同職能範疇推動智能化應用，並交付值得信賴的業務成果。」 在 SAP Connect 上，客戶們分享了Autonomous Enterprise正如何為其業務帶來可量
  7. AISAP推動「自主營運企業」落地應用Companies: SAP香港, 2026年10月9日 - SAP在近日舉行的 SAP Connect 大會展示「自主營運企業」（Autonomous Enterprise）的實際應用，演示 Joule Work 與智能助手 Joule Assistants 如何為各業務範疇的客戶創造價值。 SAP 全球行政總裁柯睿安（Christian Klein）表示：「這是企業級業務人工智能（Business AI）的突破性時刻，自主營運企業的應用正在加速落地。透過基於 SAP Business AI 平台構建的 Joule 及 SAP Autonomous Suite，我們正協助諾華（Novartis）、Morgan Foods、雀巢（Nestlé）及普華永道（PwC）等機構，在不同職能範疇推動智能化應用，並交付值得信賴的業務成果。」 在 SAP Connect 上，客戶們分享了Autonomous Enterprise正如何為其業務帶來可量化的價值： - 諾華採購負責人 Christoph Buerki表示：「我們與SAP共同研發的Joule Sourcing Assistant於近期已推出先導項目，其願景是讓AI Agent承接處理繁重且重複的工作，讓採購專業人員能夠專注於制定策略、與供應商協作及創造價值。」 - Morgan Foods首席財務官Steve Hankins表示：「我們已經著手為Agent應用做好準備，尤其是在技術基礎層面。最大的轉變將是從被動響應轉向預測性管理，Agent能夠比以往更快地連接需求信號、庫存水平及供應商狀態。我們的『超能力』來自人與Agent的協同。我們約 1,000 名員工是供應鏈運轉的根本，技術則讓他們發揮得更好。」 - 雀巢全球IT創新與企業架構負責人Luca Dell'Orletta表示：「我們在 140 個國家推進 SAP S/4HANA 轉型，正在構建一個互聯的數字核心，透過統一的流程、可信的數據以及跨市場和業務職能的更高可視性，為企業奠定堅實基礎。在此基礎上，Joule 與Accounts Receivable Assistant能夠根據風險和業務背景自動確定催收工作的優先等級，推薦下一步最佳行動，並協助財務團隊更快應對變化。」 - 普華永道首席會計官、財務總監及業務服務負責人Jill Notz表示：「在專業服務領域，賬單開發可能是最容易出錯的流程之一，而準確性對於客戶體驗至關重要。SAP Billing Assistant為這一關鍵流程注入更強的智能，協助更早識別潛在問題，幫助員工為客戶帶來更好的成果，並建立更牢固的客戶關係。在 Billing Assistant 取得成功的基礎上，普華永道與 SAP 正進一步拓展合作，在更多領域開展聯合 AI 創新。」 SAP 推動「自主營運企業」規模化發展 Joule Work 開始面向客戶推出，作為全新的 AI 用戶交互界面，讓員工能夠使用自然語言與 SAP 解決方案進行交互，並跨 SAP 及第三方數據完成工作。 依托 SAP Knowledge Graph 提供的業務語義上下文，該知識圖譜涵蓋逾 700 萬個數據字段，Joule 可以為用戶提供可靠的信息。 在 SAP 內部，Joule Work 已經服務於 11 萬名員工，公司在財務、人力資源及採購等領域實現 20% 的生產力提升。部分客戶也已在其業務環境中使用 Joule Work。 Maschinenfabrik Reinhausen複雜性管理總監 Peter Wied表示：「作為 SAP 客戶已有 28 年，我們與 SAP 在 AI 轉型之旅及 Joule Work Desktop 早期採用計劃上的合作，短短幾個月內取得的推進速度和勢頭，遠超我們過去多年的經驗。過去，在 SAP S/4HANA 環境中完成一些工作可能需要長達一小時的手動操作；如今，通過慣用語言，只需幾秒鐘即可完成。這從根本上改變了我們的團隊與業務數據交互的方式。」 CONA Services的SAP 平台架構師Keith Smith表示：「SAP 專屬團隊表現非常出色。他們積極主動地溝通，專注於加速架構啟用，快速解決缺陷，並提供全面支援，使我們能夠比在沒有他們幫助的情況下自行應對這些挑戰，更早做好 Joule 的準備。CONA 團隊對目前取得的進展感到振奮，並期待在未來幾個月繼續推進採用，同時進一步探索和測試 Joule 的各項能力。」 當單純查詢不足以滿足客戶需求時，Joule Assistants可以直接在業務工作流中執行營運任務，並利用既有的數據、授權機制和審計軌跡。客戶可以自主控制 AI 的自動化程度。SAP 的方法同樣強調開放性：透過 Agent2Agent 協議，Joule 可以與第三方 AI 和Agent連接，將受管理的業務語義上下文引入更廣泛的 AI 工作流。 在 SAP Connect 大會上，SAP 展示了這些能力如何透過 SAP Autonomous Suite在不同業務領域創造實際成果： - 財務領域：財務管理人員可自動化收入確認、信息披露及貿易合規等流程；International Trade Assistant的早期部署已將貿易分類工作減少多達 50%。 - 供應鏈領域：計劃人員可以將原本需要數小時處理的供應鏈中斷問題，轉化為跨計劃、製造和物流的一鍵解決。 - 人力資源領域：領導者可確定填補人力缺口的更佳做式，員工也可根據自身需要作出更明智的福利選擇。 - 採購領域：決策者可以透過與內置行業基準進行比較，識別節省成本的機會，並管理整個外部勞動力生命週期。 - 客戶體驗領域：企業可借助 AI 驅動的營銷活動、報價與客戶工作流程，將客戶互動轉化為銷售機會。 - 行業應用：SAP 正與不同客戶合作，將 AI 應用於專業化的行業業務流程，幫助製造、零售、大宗商品交易及資產密集型行業的企業改善決策、自動執行常規任務，並構建更具韌性的營運體系。 打造可信的商業AI平台 SAP Business AI 平台為企業提供統一的 AI 能力賦能平台，用於在 SAP 及第三方環境中構建、賦予業務語義情境並管理 AI。借助 Joule Studio，業務用戶與開發人員可透過無代碼到專業代碼工作流程，構建與擴展技能及Agent，並可從 70 多個 AI 模型中進行選擇。SAP Business Data Cloud與 SAP Knowledge Graph 為這些Agent提供可信的業務數據和情境支撐，幫助企業為每個使用場景選擇合適的模型，並更好地管理 AI 價值和使用情況。 SAP 提供的管理能力幫助企業以透明、負責任且可控的方式規模化部署 AI。 SAP LeanIX 解決方案中的 SAP AI Agent Hub 提供企業Agent的集中化清單管理，而 SAP 獨立通過 ISO/IEC 42001 認證的管理架構，則支援合規要求、既定授權和可審核的 AI 運營。 為了幫助企業實現 AI 的規模化採用，SAP 的Business Transformation Management產品組合，包括 SAP Signavio、SAP LeanIX 及 SAP WalkMe 解決方案，提供完整工具鏈，用於分析業務流程、管理應用和Agent，並推動整個企業範圍內的採用。 SAP將嵌入式支付引入Cloud ERP SAP 同時宣布正式進入支付市場，推出由 SAP 旗下公司 Tereina 提供支持的 SAP Pay。 SAP Pay 直接嵌入 SAP Cloud ERP。當帳單到期時，SAP Pay 可以在同一業務工作流中執行並完成支付對賬，從而減少人工文件處理和對外部處理流程的依賴，同時為客戶提供更強的控制能力。 合作夥伴拓展自主業務的應用範圍 SAP 正通過一系列新的合作夥伴關係，將自主營運企業能力拓展至 SAP 自身應用組合之外，把專業化智能能力直接帶入 SAP 工作流程。 SAP與穆迪（Moody's Corporation）的新合作旨在將穆迪的供應商風險監控數據嵌入 SAP Ariba Supplier Lifecycle and Performance。 這讓採購團隊能夠在決策時持續獲取有關供應商財務健康狀況、營運風險和合規狀態的持續更新洞察。 企業將能夠從定期風險審查轉向持續監控，使 Joule Agent能夠在中斷影響業務之前預警供應商風險信號，並提供替代方案。 與ORO Labs的擴展合作，將採購編排能力作為解決方案擴展帶給 SAP 客戶。 由 ORO Labs 提供的 SAP Ariba Procurement Orchestration解決方案是專門打造的採購編排層，能夠在異構企業環境中端到端連接採購工作流，為業務用戶在需求提交、任務執行和全流程可視化方面提供無縫體驗。 更多內容請參閱：《2026 Connect 創新新聞指南》
  8. AI从Ⅲ期临床到商业化合作 德睿智药的AI制药价值逐步显现香港, 2026年10月9日 - (亚太商讯) - AI制药进入准商业化阶段，德睿智药迎来关键业务进展 AI究竟能为新药研发创造多大价值？对于关注这一领域的投资人而言，答案需要在具体的药物和业务进展中寻找。研发平台能否持续产出候选药物，核心产品能否取得临床进展，以及研发成果能否获得产业合作伙伴认可，共同构成了判断一家AI制药企业成长潜力的重要依据。 杭州德睿智药科技有限公司（MindRank，以下简称“德睿智药”）近期披露的商业化合作，为观察这一问题提供了新的窗口。 2026年9月28日，德睿智药宣布，与三生制药（01530.HK）旗下三生蔓迪及万晟医药，就其自主研发的AI设计口服小分子GLP-1受体激动剂MDR-001达成独家商业化合作，覆盖中国内地、香港及澳门，潜在总交易金额最高可达人民币17.5亿元，并可获高比例销售分成。该产品目前正在中国开展针对成人肥胖或超重人群的Ⅲ期关键临床研究。 对于德睿智药这家临床阶段AI Nat
  9. AI蘋果Home Hub傳聞升溫 家庭AI中樞的落地賽已開啟近期，據多家媒體援引 Bloomberg 報導，蘋果可能推出由 Siri AI 驅動的家庭中樞產品。圍繞「Home Hub」的討論升溫，再次讓家庭 AI 中樞成為科技行業關注的焦點。
  10. AI從Ⅲ期臨床到商業化合作 德睿智藥的AI製藥價值逐步顯現AI究竟能為新藥研發創造多大價值？對於關注這一領域的投資人而言，答案需要在具體的藥物和業務進展中尋找。研發平台能否持續產出候選藥物，核心產品能否取得臨床進展，以及研發成果能否獲得產業合作夥伴認
  11. FinanceFrom Phase III Trials to Commercialization Partnerships, MindRank's AI Drug Development Value Comes into FocusHong Kong, Oct 9, 2026 - As AI Drug Development Approaches Commercialization, MindRank Marks a Key Business Milestone How much value can AI create in the discovery and development of new medicines' For investors following the sector, the answer lies in tangible progress in drug development and business execution. A platform’s ability to consistently generate drug candidates, advance lead assets through clinical development and secure recognition from industry partners provides an important basis for assessing an AI drug developer’s growth potential. The recently announced commercialization partnership by MindRank AI Ltd. (MindRank, hereinafter “MindRank”) offers a new window into this question. On September 28, 2026, MindRank announced an exclusive commercialization partnership with 3SBio (01530.HK) subsidiaries Sunshine Mandi and Wansheng Pharmaceutical for MDR-001, its internally developed, AI-designed oral small-molecule GLP-1 receptor agonist. Covering mainland China, Hong Kong and Macau, the agreement carries a potential total transaction value of up to RMB1.75 billion, alongside a substantial share of sales revenue. MDR-001 is currently undergoing a pivotal Phase III clinical trial in China in adults with obesity or overweight. For MindRank, a clinical-stage AI-native drug discovery and development technology company, the partnership further connects drug development with commercialization planning. It lays the groundwork for marketing its lead asset following potential approval and establishes a clearer pathway for translating AI-driven research into commercial value. As its lead asset advances through pivotal clinical development, MindRank has begun preparing for post-approval marketing and channel coverage, extending the product’s development pathway into commercialization. Under the agreement, Sunshine Mandi and Wansheng Pharmaceutical will provide exclusive, comprehensive services and distribution across all channels following MDR-001’s launch. MindRank will retain all rights, title and interests in the product’s intellectual property and remain responsible for clinical development, regulatory submissions, manufacturing and supply. The transaction includes up to RMB150 million in payments for collaboration rights, up to RMB1.6 billion in royalty payments upon the fulfillment of agreed conditions, and a substantial share of sales revenue. From a business-model perspective, the agreement establishes a clear division of responsibilities. MindRank will continue investing in research and product development, while its partners will provide exclusive, comprehensive services and distribution across all channels within the agreed territories following regulatory approval and launch. In an industry that requires sustained investment, this collaboration could help MindRank retain its core asset rights while drawing on its partners’ commercial capabilities to support launch preparations and focus its own resources on strengthening its core capabilities. The partners’ willingness to make commercialization arrangements for an investigational drug also provides a new reference point for assessing its potential industry value. Clinical data address whether a product merits further development, while commercial partnerships indicate whether industry participants are willing to take part in its subsequent development. Together, these elements make MindRank’s growth story more tangible. A Lead Asset in Phase III Provides a Clearer Basis for Assessing AI-Driven R&D Capabilities The core asset underpinning the partnership is MDR-001, which continues to advance through development. In February 2026, MindRank announced that the first participant had been dosed in MOBILE, its Phase III clinical trial of MDR-001. According to the company, the multicenter, randomized, double-blind, placebo-controlled study plans to enroll approximately 750 participants across around 50 clinical centers in China to further evaluate the product’s long-term efficacy and safety. This means the evidence available to assess MindRank’s AI-driven R&D capabilities now extends to larger-scale, late-stage clinical research. For investors, the lead asset’s entry into Phase III sharpens the focus on several key questions: whether long-term efficacy can be further validated, whether safety and tolerability findings can be sustained, and whether the product can establish clinically meaningful competitive advantages. Previously disclosed Phase IIb findings supported further development. In the study, which enrolled 317 adults with obesity or overweight, participants in the MDR-001 dose groups achieved mean reductions in body weight from baseline of 8.2% to 10.3% after 24 weeks, compared with 2.5% in the placebo group. The rate of treatment discontinuation due to treatment-emergent adverse events was 0.8%. Common adverse events were primarily gastrointestinal and mostly mild to moderate. These findings remain subject to further validation in subsequent studies. For weight-management medicines, product value depends on a combination of weight-loss efficacy, long-term safety, tolerability and ease of use. Compared with the injectable peptide-based GLP-1 medicines that currently dominate the market, MDR-001’s oral small-molecule formulation can significantly improve medication adherence, while its large-scale manufacturing costs are substantially lower than those of peptide-based medicines, offering considerable market potential and commercial value. These attributes provide a promising direction for its future product positioning, although translating them into a competitive advantage will require continued accumulation of clinical evidence. Beyond progress in product development, R&D efficiency is another important lens through which to assess MindRank. According to the company, MDR-001 progressed from project initiation to preclinical candidate (PCC) nomination in just eight months, during which approximately 80 small molecules were synthesized. Its investigational new drug (IND) application was cleared in the United States within 19 months of project initiation and MDR-001 advanced to Phase III in China in approximately 4.5 years. In its July 2026 financing announcement, the company further disclosed that cumulative direct R&D investment in the program, from initiation through the start of Phase III in China, totaled approximately US$23 million. These timelines and investment figures provide a more concrete basis for understanding how MindRank organizes drug discovery and development. For drug developers, development timelines and funding requirements directly affect how many programs they can advance, how long they can sustain development and how they allocate resources to subsequent work. AI’s commercial significance must also be assessed within these real-world R&D constraints. As a flagship application of MindRank’s AI-driven drug discovery and development system, MDR-001 offers a traceable development pathway: from molecular design to clinical research and, subsequently, commercialization partnerships. The platform’s capabilities are beginning to be tested through tangible business outcomes. This provides capital markets with a more useful basis for understanding the company’s technology value than descriptions of algorithms or model parameters alone. Beyond the Lead Asset, Long-Term Growth Depends on Sustained Platform Output MDR-001 is the central focus of MindRank’s business progress at this stage, while the company’s long-term growth potential also depends on its ability to continue developing new drug assets. According to the MindRank, its end-to-end AI drug development engine, MAP (Molecule Arts Platform), integrates biology, chemistry, computation, experimental validation and clinical learning into a unified drug discovery and development system. In July 2026, the company announced that it had completed a cumulative US$52 million Series B financing in stages, with proceeds earmarked for further platform development and the advancement of its clinical and preclinical pipeline. In September 2026, the company formally launched Intera (Intelligence Era), its life-sciences foundation model system, and released a technical report on InteraFold-Chem, the first model in the InteraFold series. From an operating perspective, platform development and pipeline advancement have the potential to reinforce each other. R&D programs bring real-world problems and experimental feedback to the platform, while platform iterations support the discovery and optimization of subsequent programs. Ultimately, the platform’s value must be reflected in sustained output: its ability to advance more molecules with development potential across different targets and disease areas, gradually building a business supported by multiple assets. MindRank has already expanded beyond metabolic diseases. In March 2025, the company disclosed that MRANK-106, an oral dual inhibitor of WEE1 and YES1, had received IND approval in the U.S. in oncology. This development provides another case through which to assess the applicability of its AI platform across different R&D areas, although the product’s potential remains subject to subsequent clinical validation. In earlier-stage research, the company disclosed in April 2026 that a collaborative study on drug discovery for Alzheimer’s disease, conducted by MindRank, the University of Macau and Imperial College London, had been published in Nature Biomedical Engineering. The work combined AI screening with experimental validation to identify small molecules meriting further investigation, demonstrating the company’s research capabilities and exploration at the forefront of drug discovery for complex diseases. These programs are at different stages, and their contributions to the company’s value need to be assessed separately. MDR-001 remains the main focus of current clinical development and commercialization preparations, while other pipeline programs and research support the platform’s broader applicability and long-term project portfolio. As more programs deliver verifiable progress, outside observers will be better positioned to assess whether the company can consistently replicate its R&D capabilities. Viewed through this lens, the recent commercialization partnership offers an opportunity to reassess MindRank. Its lead asset has entered pivotal clinical development, partners are participating in commercialization preparations at an early stage, financing supports continued R&D, and its presence across multiple areas preserves opportunities for future growth. These interconnected developments make the company’s development trajectory easier for capital markets to understand. MDR-001 remains in clinical development and has not yet received marketing approval. Its future value realization depends on clinical results, regulatory approval and commercial execution. Nevertheless, the business progress achieved to date provides a more concrete basis for assessing MindRank. For investors following opportunities at the intersection of AI and innovative medicines, the central question worth tracking is whether the company can progressively translate its established R&D capabilities into more verifiable drug assets and commercial outcomes.
  12. AI從Ⅲ期臨床到商業化合作 德睿智藥的AI製藥價值逐步顯現香港, 2026年10月9日 - AI製藥進入準商業化階段，德睿智藥迎來關鍵業務進展 AI究竟能為新藥研發創造多大價值？對於關注這一領域的投資人而言，答案需要在具體的藥物和業務進展中尋找。研發平台能否持續產出候選藥物，核心產品能否取得臨床進展，以及研發成果能否獲得產業合作夥伴認可，共同構成了判斷一家AI製藥企業成長潛力的重要依據。 杭州德睿智藥科技有限公司（MindRank，以下簡稱「德睿智藥」）近期披露的商業化合作，為觀察這一問題提供了新的窗口。 2026年9月28日，德睿智藥宣布，與三生製藥（01530.HK）旗下三生蔓迪及萬晟醫藥，就其自主研發的AI設計口服小分子GLP-1受體激動劑MDR-001達成獨家商業化合作，覆蓋中國內地、香港及澳門，潛在總交易金額最高可達人民幣17.5億元，並可獲高比例銷售分成。該產品目前正在中國開展針對成人肥胖或超重人群的Ⅲ期關鍵臨床研究。 對於德睿智藥這家臨床階段AI Nat